14.5 MOUNJARO Use in Combination with Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus SURPASS-PEDS (NCT05260021) was a 30-week double-blind, placebo-controlled trial with a 22-week open-label extension that randomized 99 pediatric patients 10 years of age and older with type 2 diabetes mellitus with inadequate glycemic control on metformin (69%), or basal insulin (8%), or both (23%) to receive subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or placebo once weekly as add-on therapy
Well, working a night shift or early in the morning, taking irate calls makes you grumpy all the time especially if you have also personal issues
What benefits are reported
These damages disrupt the integrity of the genetic code and inheritance for the mitochondrial and nuclear genomes
This reduces long-term costs compared to clinic-dependent approaches, though it places more responsibility on the researcher for proper technique and consistency